Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 1, 2019Journal of the Advanced Practitioner in OncologyOpen Access

CAR T-Cell Therapy: Adverse Events and Management

View Full Paper
Ask AI
Bookmark
Share

Authors

SASherry AdkinsThe University of Texas MD Anderson Cancer Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Sherry Adkins (2019) studied this question.

synapsesocial.com/papers/698e2a1ab0728b1abf3b574ehttps://doi.org/10.6004/jadpro.2019.10.4.11
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia2013 · 57 citations
  2. 2Current concepts in the diagnosis and management of cytokine release syndrome2014 · 2,855 citations
  3. 3Chimeric Antigen Receptor T Cell Therapy and the Kidney2018 · 63 citations
  4. 4Cytokine-Release Syndrome: Overview and Nursing Implications2007 · 85 citations
  5. 5Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy2018 · 266 citations